The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
Open accessAbstract
Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies target the primary tumour rather than metastases and have a limited efficacy in the treatment of metastatic disease. Metastatic cells have specific features that render them less sensitive to therapy and targeting these features might enhance the efficacy of current treatment. A detailed study of the biological characteristics and behaviour of metastatic OS cells may provide a rational basis for innovative treatment strategies. The aim of this review is to give an overview of the biological changes in metastatic OS cells and the preclinical and clinical efforts targeting the different steps in OS metastases and how these contribute to designing a metastasis directed treatment for OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 1×
“The 5-year survival rate for OS patients with metastases is 20% compared to 65% for patients with localised disease and most deaths associated with OS are the result of metastatic disease [5, 8–11].”
BackgroundMirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S. M., & Helman, L. J. (2004) · Nature Medicine · doi:10.1038/nm982 · Cited by 705
Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., et al. (2009) · Cancer · doi:10.1002/cncr.24566 · Cited by 245
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype
Almog, N., Ma, L., Raychowdhury, R., Schwager, C., Erber, R., Short, S., Hlatky, L., Vajkoczy, P., Huber, P. E., Folkman, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2590 · Cited by 240
Bacci, G., Rocca, M., Salone, M., Balladelli, A., Ferrari, S., Palmerini, E., Forni, C., & Briccoli, A. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21140 · Cited by 203
Cited by
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Review of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 395
Osteosarcoma: a review of current and future therapeutic approaches
Zhao, X., Wu, Q., Gong, X., Liu, J., & Ma, Y. (2021) · BioMedical Engineering OnLine · doi:10.1186/s12938-021-00860-0 · Cited by 312
Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs
Namløs, H. M., Meza-Zepeda, L. A., Barøy, T., Østensen, I. H. G., Kresse, S. H., Kuijjer, M. L., Serra, M., Bürger, H., Cleton-Jansen, A.-M., & Myklebost, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048086 · Cited by 264
Martin, J. W., Squire, J. A., & Zielenska, M. (2012) · Sarcoma · doi:10.1155/2012/627254 · Cited by 252
Metadata
- Authors
- PosthumaDeBoer, J., Witlox, M. A., Kaspers, G. J. L., & van Royen, B. J.
- Venue
- Clinical & Experimental Metastasis
- Published
- 2011-04-02
- Volume
- 28
- Issue
- 5
- Pages
- 493-503
- ISSN
- 0262-0898 (ISSN-L)
- 1573-7276
- OpenAlex
- W2170334668
- Cited by
- 194
- References
- 7
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. https://app.cochat.ai/papers/10.1007/s10585-011-9384-x
- The paper
- PosthumaDeBoer, J., Witlox, M. A., Kaspers, G. J. L., & van Royen, B. J. (2011). Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clinical & Experimental Metastasis. https://doi.org/10.1007/s10585-011-9384-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.